Men using testosterone gel experienced improvements in sex drive, sexual activity, and erectile function.
Results showed a decreased prevalence of anemia and components of metabolic syndrome after 54 weeks of treatment.
Both low testosterone and sarcopenia tied to increased mortality, with low testosterone being a better predictor.
Daily topical testosterone restored normal testosterone levels in hypogonadal men
Sexual function and mood and depressive symptoms were improved in older men who received testosterone therapy.
Selective estrogen receptor modulators may offer a viable treatment option for men with secondary hypogonadism.
Researchers found an increased odds of low testosterone with exposure as well as an increased odds with increasing age and comorbidities.
Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the U.S. and Mexico will be terminated as of June 30, 2016.
Eating more protein may lower testosterone levels in women.
American Association of Clinical Endocrinologists issues position statement on CV risks of testosterone therapy.
Experts suggest that more studies are necessary to evaluate testosterone therapy in men with age-related hypogonadism.
Researchers observed no impact on rate of change of intima-media thickness, coronary artery calcium score.
Prostate cancer is more likely to be found in men with low testosterone vs. those with normal levels.
Quality studies are still needed to answer crucial questions about TRT and prostate cancer, cardiovascular risk.
These findings are based on data from more than 30,000 American men aged 40 years and older.
Undergoing testosterone replacement therapy didn't improve ejaculatory dysfunction in men with testosterone deficiency.
More than half have depression or depressive symptoms, and 25% are taking antidepressants.
Findings in older men with high cholesterol and low testosterone.
The benefits of testosterone therapy outweigh the risks, according to experts, and the FDA may need to rethink its stance.
High levels of free testosterone and bioavailable testosterone, and low levels of sex hormone-binding globulin, are tied to a decreased risk for erectile dysfunction.
New data from two studies indicate that testosterone therapy is not associated with cardiovascular risks, which challenges recent FDA decisions.
Three doses of testosterone nasal gel may help normalize testosterone levels in men with hypogonadism.
Low-dose letrozole may help treat infertility in men with obesity-related hypogonadotropic hypogonadism.
The agency now requires prescription testosterone product labels to clarify the approved use of these medications and information on potential increased risks for heart attacks and stroke.
Devices include remote heartbeat monitor, fitness smart socks and devices for monitoring glucose.
In older men, testosterone levels directly linked to sexual activity, desire.
Increases in total testosterone levels, testosterone secretion index values in middle-aged men.
Low serum testosterone appears to be linked to adverse outcomes in men with type 2 diabetes.
Long-term testosterone therapy did not increase incidence of prostate cancer in hypogonadal men.
Testosterone testing appears to be increasing, especially among men with comorbidities associated with hypogonadism.
The presence of axillary hair or use of deoderant or antiperspirant did not affect the absorption of a testosterone solution.
Hypogonadism is disproportionately high in men with spinal cord injury, leading researchers to suggest a connection between the two conditions.
Older men with lower baseline testosterone experience greater increases in prostate-specific antigen with testosterone gel use.
Low testosterone may increase cardiovascular risk in middle-aged men with type 2 diabetes.
In rats, testosterone appeared to raise the risk for prostate tumor growth.
A new Endocrine Society clinical practice guideline advises against the use of testosterone in healthy women.
Lipocine announced top-line results from its Phase 3 SOAR clinical trial evaluating the efficacy and safety of LPCN 1021, an oral testosterone agent in hypogonadal men with low testosterone.
FDA panel votes 20-1 to tighten use of testosterone replacement therapy.
Expert panel to decide whether the prescribing information on testosterone drugs should be changed.
Chemicals found in many household products may reduce androgen levels in both sexes.
Upsher-Smith announced the launch of Testosterone Gel 1%, the generic version of Vogelxo gel, in 3 different configurations.
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Bariatric Surgery: An Effective Treatment for Type 2 Diabetes
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation